CEO of CRYO-CELL Mr. Dan Richard Talks Business with Wall Street Webcast

Apr 03, 2001, 01:00 ET from CRYO-CELL International, Inc.

    NEW YORK, April 3 /PRNewswire/ -- Mr. Dan Richard, Founder & CEO of
 CRYO-CELL International, Inc. (Nasdaq:   CCEL), participated in an in-depth
 interview with Wall Street Webcast that can be heard in real audio at
 http://www.wallstreetwebcast.com.
     During the course of the interview, Mr. Richard stated that the mission of
 CRYO-CELL is to inform all expectant parents as to alternatives of having
 their newborn's umbilical cord blood discarded as hospital "bio-waste"
 material. Mr. Richard pointed out that out of the 4,000,000 babies born
 annually in the United States; over 98% of their umbilical cords are "thrown
 away."  Unfortunately the stem cells contained in each of these cords have the
 ability to save lives. They are a perfect match for newborns throughout their
 lifetime and a one in four chance, or better, for matching siblings.  This is
 why over 11,000 OB/GYNs or medical caregivers support their patient's decision
 to store their newborns U-Cord(TM) stem cells with CRYO-CELL.
     When queried during the interview, Mr. Richard addressed the difference
 between the stem cells preserved by CRYO-CELL and the aborted or fetal stem
 cells, which have continually caused controversy. "We certainly understand
 people who have a firm conviction that it is wrong to negate a life to save a
 life.  Conversely, we can understand the research community's need for stem
 cells, which can be converted into other cells for finding cures for many
 diseases. Utilizing umbilical cord blood stem cells should satisfy both
 factions."  CRYO-CELL only deals with stem cells that are from babies brought
 to full term during the gestation period.  They have been nurtured by caring
 mothers.  These cells can also be converted to various types of cells such as
 neural, muscle, and bone, among others to help find treatments in the future
 for diseases that are now incurable.
     Mr. Richard explained that CRYO-CELL can play a major part in the new age
 use of genetically engineered stem cells through its subsidiary, CCEL
 Biotherapies. CRYO-CELL has entered into an exclusive agreement with the
 University of South Florida. Recently Dr. Paul Sandberg, Chair of Neuroscience
 Program Director, Center for Aging and Brain Repair at the University,
 presented at the American Association for the Advancement of Science the
 results of the University's research team, which converted cord blood stem
 cells into neural (brain) cells for the treatment of stroke in laboratory
 animals. They also will be working on research for the development of
 treatments for Parkinson's disease, Alzheimer's, severed spinal cords and
 others.  CRYO-CELL shares the patent application for the research with the
 University of South Florida and has the exclusive marketing rights to any
 pharmaceutical developed by the University utilizing umbilical cord blood for
 stem cell transplantation.
 
     About CRYO-CELL
     CRYO-CELL is engaged in cryogenic cellular storage. The company's current
 focus is on the processing and preservation of U-Cord(TM) stem cells for
 autologous/sibling use. CRYO-CELL pioneered several technologies for the
 processing and long-term storage of specimens in a cryogenic environment. The
 company's mission since inception of affordability for U-Cord preservation
 remains in effect. The initial price of $275 includes the collection kit,
 processing, testing and first year's storage fee and the $50 annual fee is
 fixed for specimens already in storage. They developed and patented the
 world's first computer controlled, robotically-operated, laser scanning
 cellular storage unit. CRYO-CELL is the fastest growing and largest exclusive
 autologous, computer-controlled, cellular storage company in existence.
 
     About Wall Street Webcast
     Wall Street Webcast is a newly developed website devoted to the principal
 business model of conducting formatted interviews with Small Cap to Mid Cap
 companies that have important news and upcoming events. In concert with
 commentary from leading market analysts, portfolio managers and fund managers,
 wallstreetwebcast is able to create a space on the internet where
 sophisticated investors can come for timely quality information about
 investing in capital markets.
 
     Forward-Looking Statement
     Statements wherein the terms "believes," "intends," "projects" or
 "expects" as used are intended to reflect "forward-looking statements" of the
 Company.  The information contained herein is subject to various risks,
 uncertainties and other factors that could cause actual results to differ
 materially from the results anticipated in such forward-looking statements or
 paragraphs. Readers should carefully review the risk factors described in
 other documents the Company files from time to time with the Securities and
 Exchange Commission, including the most recent Annual Report on Form 10-K,
 Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by
 the Company.
 
 

SOURCE CRYO-CELL International, Inc.
    NEW YORK, April 3 /PRNewswire/ -- Mr. Dan Richard, Founder & CEO of
 CRYO-CELL International, Inc. (Nasdaq:   CCEL), participated in an in-depth
 interview with Wall Street Webcast that can be heard in real audio at
 http://www.wallstreetwebcast.com.
     During the course of the interview, Mr. Richard stated that the mission of
 CRYO-CELL is to inform all expectant parents as to alternatives of having
 their newborn's umbilical cord blood discarded as hospital "bio-waste"
 material. Mr. Richard pointed out that out of the 4,000,000 babies born
 annually in the United States; over 98% of their umbilical cords are "thrown
 away."  Unfortunately the stem cells contained in each of these cords have the
 ability to save lives. They are a perfect match for newborns throughout their
 lifetime and a one in four chance, or better, for matching siblings.  This is
 why over 11,000 OB/GYNs or medical caregivers support their patient's decision
 to store their newborns U-Cord(TM) stem cells with CRYO-CELL.
     When queried during the interview, Mr. Richard addressed the difference
 between the stem cells preserved by CRYO-CELL and the aborted or fetal stem
 cells, which have continually caused controversy. "We certainly understand
 people who have a firm conviction that it is wrong to negate a life to save a
 life.  Conversely, we can understand the research community's need for stem
 cells, which can be converted into other cells for finding cures for many
 diseases. Utilizing umbilical cord blood stem cells should satisfy both
 factions."  CRYO-CELL only deals with stem cells that are from babies brought
 to full term during the gestation period.  They have been nurtured by caring
 mothers.  These cells can also be converted to various types of cells such as
 neural, muscle, and bone, among others to help find treatments in the future
 for diseases that are now incurable.
     Mr. Richard explained that CRYO-CELL can play a major part in the new age
 use of genetically engineered stem cells through its subsidiary, CCEL
 Biotherapies. CRYO-CELL has entered into an exclusive agreement with the
 University of South Florida. Recently Dr. Paul Sandberg, Chair of Neuroscience
 Program Director, Center for Aging and Brain Repair at the University,
 presented at the American Association for the Advancement of Science the
 results of the University's research team, which converted cord blood stem
 cells into neural (brain) cells for the treatment of stroke in laboratory
 animals. They also will be working on research for the development of
 treatments for Parkinson's disease, Alzheimer's, severed spinal cords and
 others.  CRYO-CELL shares the patent application for the research with the
 University of South Florida and has the exclusive marketing rights to any
 pharmaceutical developed by the University utilizing umbilical cord blood for
 stem cell transplantation.
 
     About CRYO-CELL
     CRYO-CELL is engaged in cryogenic cellular storage. The company's current
 focus is on the processing and preservation of U-Cord(TM) stem cells for
 autologous/sibling use. CRYO-CELL pioneered several technologies for the
 processing and long-term storage of specimens in a cryogenic environment. The
 company's mission since inception of affordability for U-Cord preservation
 remains in effect. The initial price of $275 includes the collection kit,
 processing, testing and first year's storage fee and the $50 annual fee is
 fixed for specimens already in storage. They developed and patented the
 world's first computer controlled, robotically-operated, laser scanning
 cellular storage unit. CRYO-CELL is the fastest growing and largest exclusive
 autologous, computer-controlled, cellular storage company in existence.
 
     About Wall Street Webcast
     Wall Street Webcast is a newly developed website devoted to the principal
 business model of conducting formatted interviews with Small Cap to Mid Cap
 companies that have important news and upcoming events. In concert with
 commentary from leading market analysts, portfolio managers and fund managers,
 wallstreetwebcast is able to create a space on the internet where
 sophisticated investors can come for timely quality information about
 investing in capital markets.
 
     Forward-Looking Statement
     Statements wherein the terms "believes," "intends," "projects" or
 "expects" as used are intended to reflect "forward-looking statements" of the
 Company.  The information contained herein is subject to various risks,
 uncertainties and other factors that could cause actual results to differ
 materially from the results anticipated in such forward-looking statements or
 paragraphs. Readers should carefully review the risk factors described in
 other documents the Company files from time to time with the Securities and
 Exchange Commission, including the most recent Annual Report on Form 10-K,
 Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by
 the Company.
 
 SOURCE  CRYO-CELL International, Inc.